- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07454148
CART-BP Prospectieve Studie voor Hypertensiecontrole
Efficaciteit en Veiligheid van CART BP Pro-Gestuurd Bloeddrukbeheer bij Koreaanse Patiënten met Ongecontroleerde Hypertensie: Een Prospectieve Niet-Gerandomiseerde Studie
This prospective, open-label, non-randomized study evaluates the effectiveness and safety of a CART BP pro(a brand name of cuffless ambulatory blood pressure monitoring device)-guided blood pressure management strategy in Korean patients with uncontrolled hypertension. Participants are allocated to either a CART BP pro-guided management group or a usual care group based on clinical decision and participant preference. The primary efficacy endpoint is 24-hour mean ambulatory systolic blood pressure at 24 weeks; safety outcomes including treatment-emergent adverse events (TEAEs) are also assessed.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Hypertension remains suboptimally controlled despite combination pharmacotherapy, and office blood pressure measurements may not adequately reflect true ambulatory blood pressure burden and nocturnal patterns. CART BP pro is a wearable, cuffless photoplethysmography-based continuous blood pressure monitoring device. This study investigates whether a CART BP pro-guided antihypertensive titration strategy improves 24-hour ambulatory blood pressure control compared with usual care in real-world outpatient settings. Participants receive standard antihypertensive medications (e.g., angiotensin receptor blocker [ARB], calcium channel blocker [CCB], thiazide diuretic) per guideline-based care. In the CART BP pro-guided group, medication adjustments are informed by CART BP pro-derived 24-hour blood pressure data. The planned follow-up was 24 weeks. Prospective data collection under this non-randomized study protocol has ended. The optional extension to 48 weeks was not undertaken. A separate randomized controlled trial, CARTBP-HTN-P2-2025 (NCT07465549), is ongoing to evaluate CART BP pro-guided blood pressure management under a randomized design. Any future analyses of routinely collected clinical data would be retrospective and subject to applicable institutional review board and consent requirements.
The total actual enrollment was 286 participants. The initial publication (PMID: 42846709) reported a subcohort of 246 participants (67 in the CART BP arm and 179 in the usual-care arm) using data available as of April 6, 2026. Eight participants were lost to follow-up. Of the remaining 238 participants, 162 had valid follow-up ambulatory blood pressure recordings and were included in the primary analysis (38 in the CART BP arm and 124 in the usual-care arm); 76 did not have a valid recording. These publication-specific populations are distinct from the total enrollment of the study.
The registered primary outcome is 24-hour mean ambulatory systolic blood pressure at 24 weeks. The publication described the outcome assessment as the 6-month visit and reported median recording times of 181 days after the index visit in the CART BP arm and 188 days in the usual-care arm. Both arms were scheduled to undergo CART BP pro recording for the outcome assessment. Because ambulatory blood pressure was not systematically measured at baseline, the published primary endpoint was the follow-up blood pressure level, not within-participant change from baseline.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Choose One...
-
Seoul, Choose One..., Zuid -Korea, 02841
- Korea University Anam Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age >= 19 years
- Office systolic blood pressure(BP) >= 140 mmHg or diastolic BP >= 90 mmHg
- Able and willing to provide written informed consent and comply with follow-up visits
Exclusion Criteria:
- History of intolerance to olmesartan, amlodipine, or hydrochlorothiazide
- Suspected secondary hypertension
- Atrial fibrillation
- Pregnancy or lactation
- Other serious medical condition that may interfere with study participation
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: CART BP pro-guided management
Participants undergo 24-hour continuous blood pressure monitoring with CART BP pro. Antihypertensive medications are adjusted based on ambulatory blood pressure data. |
Wearable cuffless continuous blood pressure monitoring device. |
|
Actieve vergelijker: Usual care
Participants receive antihypertensive medication adjustments based on office blood pressure measurements according to standard clinical practice. |
Standard hypertension management based on office blood pressure. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
24-hour mean systolic blood pressure
Tijdsspanne: 24 weeks
|
Between-group difference in 24-hour mean ambulatory systolic blood pressure measured using the CART BP Pro device at 24 weeks. |
24 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAE)
Tijdsspanne: 24 weeks
|
Proportion of participants experiencing TEAEs during the 24-week study period. |
24 weeks
|
|
24-hour blood pressure load
Tijdsspanne: 24 weeks
|
Percentage of valid ambulatory BP readings exceeding prespecified thresholds over 24 hours. |
24 weeks
|
|
Office blood pressure change
Tijdsspanne: 24 weeks
|
Change in office systolic and diastolic blood pressure from baseline to 24 weeks. |
24 weeks
|
|
Target blood pressure achievement rate
Tijdsspanne: 24 weeks
|
Proportion of participants achieving prespecified ambulatory BP targets. |
24 weeks
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CARTBP-HTN-P1-2025
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified individual participant data collected in this study are not currently planned to be shared with external researchers. Data sharing may be considered in the future subject to institutional review board approval and institutional data governance policies.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .